Top

Published in:

01-11-2012 | Original Article

Prospective observational Italian study on palliative sedation in two hospice settings: differences in casemixes and clinical care

Authors: Marco Maltoni, Guido Miccinesi, Piero Morino, Emanuela Scarpi, Francesco Bulli, Francesca Martini, Filippo Canzani, Monia Dall’Agata, Eugenio Paci, Dino Amadori

Published in: Supportive Care in Cancer | Issue 11/2012

Abstract

Purpose

Palliative sedation (PS) has been defined as the use of sedative medications to relieve intolerable suffering from refractory symptoms by a reduction in patient consciousness. It is sometimes necessary in end-of-life care when patients present refractory symptoms. We investigated PS for refractory symptoms in different hospice casemixes in order to (1) assess clinical decision-making, (2) monitor the practice of PS, and (3) examine the impact of PS on survival.

Methods

This observational longitudinal cohort study was conducted over a period of 9 months on 327 patients consecutively admitted to two 11-bed Italian hospices (A and B) with different casemixes in terms of median patient age (hospice A, 66 years vs. hospice B, 73 years; P = 0.005), mean duration of hospice stay (hospice A, 13.5 days vs. hospice B, 18.3 days; P = 0.005), and death rate (hospice A, 57.2% vs. hospice B, 89.9%; P < 0.0001). PS was monitored using the Richmond Agitation–Sedation Scale (RASS). Sedated patients constituted 22% of the total admissions and 31.9% of deceased patients, which did not prove to be significantly different in the two hospices after adjustment for casemix.

Results

Patient involvement in clinical decision-making about sedation was significantly higher in hospice B (59.3% vs. 24.4%; P = 0.007). Family involvement was 100% in both hospices. The maximum level of sedation (RASS, −5) was necessary in only 58.3% of sedated patients. Average duration of sedation was similar in the two hospices (32.2 h [range, 2.5–253.0]). Overall survival in sedated and nonsedated patients was superimposable, with a trend in favor of sedated patients.

Conclusions

PS represents a highly reproducible clinical intervention with its own indications, assessment methodologies, procedures, and results. It does not have a detrimental effect on survival.

Available only for authorised users

Costantini M, Beccaro M, Merlo F, Study Group ISDOC (2005) The last three months of life of Italian cancer patients. Methods, sample characteristics and response rate of the Italian Survey of the Dying of Cancer (ISDOC). Palliat Med 19:628–638PubMedCrossRef

Temel JS, Greer JA, Muzikansky A et al (2005) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363:733–742CrossRef

Cherny N, Catane R, Schrijvers D, Kloke M, Strasser F (2010) European Society for Medical Oncology (ESMO) program for the integration of Oncology and Palliative Care: a 5-year review of the Designated Centers’ incentive program. Ann Oncol 21:362–369PubMedCrossRef

Van der Heide A, Deliens L, Faisst K et al (2003) End-of-life decision-making in six European countries: descriptive studies. Lancet 362:345–350PubMedCrossRef

De Graeff A, Dean M (2007) Palliative sedation therapy in the last weeks of life: a literature review and recommendations for standards. J Palliat Med 10:67–85PubMedCrossRef

Carr MF, Mohr GJ (2008) Palliative sedation as part of a continuum of palliative care. J Palliat Med 11:76–81PubMedCrossRef

Maltoni M, Pittureri C, Scarpi E et al (2009) Palliative sedation therapy does not hasten death: results from a prospective multicenter study. Ann Oncol 20:1163–1169PubMedCrossRef

Sykes N, Thorns A (2003) The use of opioids and sedation at the end of life. Lancet Oncol 4:312–318PubMedCrossRef

Materstvedt LJ, Clark D, Ellershaw J et al (2003) Euthanasia and physician-assisted suicide: a view from an EAPC Ethics Task Force. Palliat Med 17:97–101PubMedCrossRef

10.

Miccinesi G, Rietjens J, Deliens L et al (2006) Continuous deep sedation: physicians’ experiences in six European countries. J Pain Symptom Manag 31:122–129CrossRef

11.

Cherny NI, Portenoy RK (1994) Sedation in the management of refractory symptoms: guidelines for evaluation and treatment. J Palliat Care 10:31–38PubMed

12.

Cherny NI, Radbruch L, Board of the European Association for Palliative Care (2009) European Association for Palliative Care (EAPC) recommended framework for the use of sedation in palliative care. Palliat Med 23:581–593PubMedCrossRef

13.

Kirk TW, Mahon MM, Palliative Sedation Task Force of the National Hospice and Palliative Care Organization Ethics Committee (2010) National Hospice and Palliative Care Organization (NHPCO) position statement and commentary on the use of palliative sedation in imminently dying terminally ill patients. J Pain Symptom Manag 39:914–923CrossRef

14.

van Dooren S, van Veluw HT, van Zuylen L et al (2009) Exploration of concerns of relatives during continuous palliative sedation of their family members with cancer. J Pain Symptom Manag 38:452–459CrossRef

15.

Morita T, Akechi T, Sugawara Y et al (2002) Practices and attitudes of Japanese oncologists and palliative care physicians concerning terminal sedation: a nationwide survey. J Clin Oncol 20:758–764PubMedCrossRef

16.

Schuman-Oliver Z, Brendel DH, Forstein M, Price BH (2008) The use of palliative sedation for existential distress: a psychiatric perspective. Harv Rev Psychiatr 16:339–351CrossRef

17.

Kaplan EL, Meier P (1958) Non parametric estimation for incomplete observation. J Am Stat Assoc 53:457–481CrossRef

18.

Lawless JS (1982) Statistical models and methods for life-time data. Wiley, New York

19.

Ventafridda V, Ripamonti C, De Conno F, Tamburini M, Cassileth BR (1990) Symptom prevalence and control during cancer patients’ last days of life. J Palliat Care 6:7–11PubMed

20.

Porta Sales J (2001) Sedation and terminal care. Eur J Palliat Care 8:97–100

21.

Peruselli C, Di Giulio P, Toscani F et al (1999) Home palliative care for terminal cancer patients: a survey on the final week of life. Palliat Med 13:233–241PubMedCrossRef

22.

Fainsinger RL, Waller A, Bercovici M et al (2000) A multicentre international study of sedation for uncontrolled symptoms in terminally ill patients. Palliat Med 14:257–265PubMedCrossRef

23.

Sessler CN, Gosnell MS, Grap J et al (2002) The Richmond Agitation–Sedation Scale. Validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med 166:1338–1344PubMedCrossRef

24.

Bruera E, Sala R, Rico MA et al (2005) Effects of parenteral hydration in terminally ill cancer patients: a preliminary study. J Clin Oncol 23:2366–2371PubMedCrossRef

25.

Good P, Cavenagh J, Mather M, Ravenscroft P (2008) Medically assisted hydration for palliative care patients. Cochrane Database Syst Rev (2):CD006273

26.

Morita T, Tsunoda J, Inoue S, Chihara S (2001) Effects of high dose opioids and sedatives on survival in terminally ill cancer patients. J Pain Symptom Manag 21:282–289CrossRef

27.

Morita T, Chinone Y, Ikenaga M et al (2005) Efficacy and safety of palliative sedation therapy: a multicenter, prospective, observational study conducted on specialized palliative care units in Japan. J Pain Symptom Manag 30:320–328CrossRef

Title: Prospective observational Italian study on palliative sedation in two hospice settings: differences in casemixes and clinical care
Authors: Marco Maltoni
Guido Miccinesi
Piero Morino
Emanuela Scarpi
Francesco Bulli
Francesca Martini
Filippo Canzani
Monia Dall’Agata
Eugenio Paci
Dino Amadori
Publication date: 01-11-2012
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 11/2012
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-012-1407-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

ACC 2024 Congress

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2012

Palliative care in poor-performance status small cell lung cancer patients: is there a mandatory role for chemotherapy?

Physicians’ self-assessment of cancer pain treatment skills—more training required

Successful treatment of intractable hiccups by oral application of lidocaine

Depression, fatigue, and health-related quality of life in head and neck cancer patients: a prospective pilot study

Analysis of ECOG performance status in head and neck squamous cell carcinoma patients: association with sociodemographical and clinical factors, and overall survival

Quality of life, fatigue and depression in Italian long-term breast cancer survivors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer